The management of treatment side effects can expand caregiver duties significantly, and can involve working more closely with ...

Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

UK Myeloma expert from Oxford, Professor Karthik Ramasamy, Clinical Director, SACT Clinical Reference Group for GenesisCare, ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (WGHP) — March is Multiple Myeloma Awareness ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

New therapies for multiple myeloma are dramatically improving prognosis and extending survival. Better disease control is prolonging remission and allowing patients to live without any sign of disease ...

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Kumar is a ...